Treatment Resistant Cancers
Diffusion
Diffusion
Weighted Mean
Clinical Trials: Overview
Trial and Error and Algorithm
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Feb 5, 2026

Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging
Published on: December 15, 2014
Savannah C Partridge1, Zheng Zhang1, David C Newitt1
1From the Department of Radiology, University of Washington, 825 Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics (Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown University, Providence, RI; American College of Radiology Imaging Network (ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N., J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn (P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group, Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham, Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and Science University, Portland, Ore (K.O.); Department of Radiology, University of Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of Women's Imaging, St Joseph's Women's Hospital, Tampa, Fla (J.S.D.).
Change in apparent diffusion coefficient (ADC) on MRI predicts pathologic complete response (pCR) to neoadjuvant chemotherapy for breast cancer. Midtreatment ADC change is especially predictive for HR+/HER2- tumors.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: